Acadia Pharma (ACAD) Misses Q1 EPS by 10c; Offers FY22 Guidance
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $27.29 --0%
Revenue Growth %: +19.3%
Financial Fact:
Net loss per common share, basic and diluted: -0.61
Today's EPS Names:
ALZN, ASPU, OCCI, More
Revenue Growth %: +19.3%
Financial Fact:
Net loss per common share, basic and diluted: -0.61
Today's EPS Names:
ALZN, ASPU, OCCI, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q1 EPS of ($0.70), $0.10 worse than the analyst estimate of ($0.60). Revenue for the quarter came in at $115.5 million versus the consensus estimate of $121.92 million.
GUIDANCE:
Acadia Pharma sees FY2022 revenue of $510-560 million, versus the consensus of $540.7 million.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HP Inc. projects mid-single-digit PC market decline in 2027
- Faraday Future unveils nine robotics devices priced from $9,990
- JPMorgan Downgrades Guangdong Marubi Biotechnology Co Ltd (603983:CH) to Underweight
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
